CONTEXT: A high ratio of plasma amyloid-beta peptide 40 (Abeta(40)) to Abeta(42), determined by both high Abeta(40) and low Abeta(42) levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Abeta(42) levels in the elderly population. OBJECTIVE: To characterize plasma Abeta(40):Abeta(42) ratio and cognitive function in elderly individuals with and without depression. DESIGN: Cross-sectional study. SETTING: Homecare agencies. PARTICIPANTS: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. MAIN OUTCOME MEASURES: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Abeta(40) and Abeta(42) peptides. RESULTS: Subjects with depression had lower plasma Abeta(42) levels (median, 14.1 vs 19.2 pg/mL; P = .006) and a higher plasma Abeta(40):Abeta(42) ratio (median, 8.9 vs 6.4; P < .001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Abeta(40):Abeta(42) ratio was associated with lower memory score (beta = -1.9, SE = 0.7, P = .006) after adjusting for potentially confounders. Relative to those without depression, "amyloid-associated depression," defined by presence of depression and a high plasma Abeta(40):Abeta(42) ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. CONCLUSION: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.
CONTEXT: A high ratio of plasma amyloid-beta peptide 40 (Abeta(40)) to Abeta(42), determined by both high Abeta(40) and low Abeta(42) levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Abeta(42) levels in the elderly population. OBJECTIVE: To characterize plasma Abeta(40):Abeta(42) ratio and cognitive function in elderly individuals with and without depression. DESIGN: Cross-sectional study. SETTING: Homecare agencies. PARTICIPANTS: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. MAIN OUTCOME MEASURES: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Abeta(40) and Abeta(42) peptides. RESULTS: Subjects with depression had lower plasma Abeta(42) levels (median, 14.1 vs 19.2 pg/mL; P = .006) and a higher plasma Abeta(40):Abeta(42) ratio (median, 8.9 vs 6.4; P < .001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Abeta(40):Abeta(42) ratio was associated with lower memory score (beta = -1.9, SE = 0.7, P = .006) after adjusting for potentially confounders. Relative to those without depression, "amyloid-associated depression," defined by presence of depression and a high plasma Abeta(40):Abeta(42) ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. CONCLUSION: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.
Authors: R G Perez; S Soriano; J D Hayes; B Ostaszewski; W Xia; D J Selkoe; X Chen; G B Stokin; E H Koo Journal: J Biol Chem Date: 1999-07-02 Impact factor: 5.157
Authors: D C Steffens; B L Plassman; M J Helms; K A Welsh-Bohmer; A M Saunders; J C Breitner Journal: Biol Psychiatry Date: 1997-04-15 Impact factor: 13.382
Authors: W Q Qiu; D M Walsh; Z Ye; K Vekrellis; J Zhang; M B Podlisny; M R Rosner; A Safavi; L B Hersh; D J Selkoe Journal: J Biol Chem Date: 1998-12-04 Impact factor: 5.157
Authors: A Assini; S Cammarata; A Vitali; M Colucci; L Giliberto; R Borghi; M L Inglese; S Volpe; S Ratto; F Dagna-Bricarelli; C Baldo; A Argusti; P Odetti; A Piccini; M Tabaton Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: A Heyman; G G Fillenbaum; K A Welsh-Bohmer; M Gearing; S S Mirra; R C Mohs; B L Peterson; C F Pieper Journal: Neurology Date: 1998-07 Impact factor: 9.910
Authors: Anand Kumar; Vladimir Kepe; Jorge R Barrio; Prabha Siddarth; Vicki Manoukian; Virginia Elderkin-Thompson; Gary W Small Journal: Arch Gen Psychiatry Date: 2011-11
Authors: Ruth T Morin; Philip Insel; Craig Nelson; Meryl Butters; David Bickford; Susan Landau; Andrew Saykin; Michael Weiner; R Scott Mackin Journal: J Int Neuropsychol Soc Date: 2019-06-24 Impact factor: 2.892
Authors: Adam P Spira; George W Rebok; Katie L Stone; Joel H Kramer; Kristine Yaffe Journal: Am J Geriatr Psychiatry Date: 2012-12 Impact factor: 4.105